Schott v. Nobilis Health Corp.

211 F. Supp. 3d 936, 2016 U.S. Dist. LEXIS 134829, 2016 WL 5539756
CourtDistrict Court, S.D. Texas
DecidedSeptember 29, 2016
DocketCIVIL ACTION NO. H-16-141
StatusPublished
Cited by2 cases

This text of 211 F. Supp. 3d 936 (Schott v. Nobilis Health Corp.) is published on Counsel Stack Legal Research, covering District Court, S.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schott v. Nobilis Health Corp., 211 F. Supp. 3d 936, 2016 U.S. Dist. LEXIS 134829, 2016 WL 5539756 (S.D. Tex. 2016).

Opinion

MEMORANDUM AND OPINION

Lee H. Rosenthal, United States District Judge

This is a putative federal securities class action. The lead plaintiff, Guenter Schott, sued Nobilis Health Corporation; its former chief executive officer, Christopher Lloyd; and two of its former chief financial officers, Kenneth Klein and Andy Chen, alleging securities fraud under § 10(b) and § 20(a) of the Exchange Act, 15 U.S.C. § 78j(b) and 78t(a), and Rule 10b-5, 17 C.F.R. § 240.10b-5. Schott sought to represent a class of investors who purchased Nobilis’s stock between April 2, 2015 and January 6, 2016. Schott allegés that during this period, the defendants knowingly made false and misleading statements to investors in Nobilis’s Securities and Exchange Commission filings about the risks associated with Nobilis’s business model and the costs of recent acquisitions. (Docket Entry No. 9).

The defendants moved to dismiss the complaint under Federal Rules of Civil Procedure 12(b)(6) and 9(b), and under the Private Securities Litigation Reform Act (PSLRA), 15 U.S.C. § 78u-4(b)(2), (Docket Entry No. 14). They argue that the amended complaint failed to allege facts giving rise to a strong inference of scienter and failed plausibly to allege loss causation. The plaintiffs responded, (Docket Entry No. 24), and the defendants replied, (Docket Entry No. 28). Based on the pleadings; the motion, response, and reply; the record; the arguments of counsel; and the relevant law, the defendants’ motion to dismiss is granted without prejudice and with leave to amend no later than October 24, 2016.

The reasons for this ruling are explained below.

I. Background

A. The Complaint Allegations

Nobilis manages and owns ambulatory surgical centers and other healthcare facilities in Texas and Arizona. (Docket Entry No. 9 ¶ 89). The complaint alleges that in December 2014, Nobilis began to pursue a new business strategy that involved “factoring receivables.” Nobilis would buy accounts receivable at a discount, paying cash to the seller and acquiring the risk of collecting on the accounts. (Id.' ¶¶ 41-44). Factoring receivables carries particular risks in the healthcare industry because payments depend on how much third-party insurance companies reimburse. (Id. ¶ 43).

In December 2014, Nobilis allegedly began its factoring-receivables business model by acquiring Athas Health, LLC, for approximately $34 million. (Id. ¶¶41, 48). Schott alleges that accounts receivable comprised 15 percent of Athas’s total assets, the largest of its assets. (Id. ¶ 53). As part of the acquisition, defendant Christopher Lloyd, Athas’s CEO, became the CEO of Nobilis. (Id. ¶ 41). After the Athas acquisition, Nobilis allegedly spent another $30 million on six more acquisitions through 2015, raising $8 million in capital by selling stock and issuing warrants and options. (Id. ¶ 48).

The Financial Accounting Standard Board’s Accounting Standards Codification (ASC) 310-10-25-3 treats factoring arrangements as loans. The amount of the receivable is regarded as the principal (an asset) and the factoring commission—the difference between the price paid for the account and the amount ultimately collected—is regarded as interest (a liability) over the period of the loan, from the date [944]*944of acquisition to the date a patient or her insurer settles the account. (Id. ¶ 46). Various subsections under ACS 815 require that warrants and options be recorded as liabilities at fair market value. At the end of each reporting period, a company should report changes in the fair market value of the warrants and options as income or expenses, depending on whether the fair market value increases or decreases. (Id. ¶ 49).

The parties do not dispute that Nobilis improperly accounted for its factoring receivables and its warrants and options through 2015. (Id. ¶¶ 46-50; Docket Entry No. 14 at 3-4). Instead of booking only the price paid for an account receivable as an asset, Nobilis booked the entire amount of the receivable and recorded liabilities from underpaid accounts at the time of settlement, rather than over the life of the account. (Docket Entry No. 9 ¶ 47; Docket Entry No. 14 at 3^4). And instead of recording warrants and options as liabilities, Nobilis incorrectly booked them as equity. (Docket Entry No. 9 ¶¶ 49-50; Docket Entry No. 14 at 3^4).

On January 5, 2016, Nobilis filed a Form 8-K with the SEC, disclosing its previously improper accounting and reporting how it expected the proper accounting methods to alter the positions it had stated on its SEC filings from December 2014 through 2015. Properly accounting for factoring of accounts receivable decreased Nobilis’s assets by $1.7 million, decreased liabilities by $0.3 million, and increased goodwill by $1.4 million. Properly classifying warrants and options reclassified $2.4 million from equity to liabilities, recognized $442 thousand in additional income in 2013, and recognized $3.7 million in additional expenses for 2014. (Docket Entry No. 9 ¶ 73).

On January 13, 2016, Nobilis filed its Form 10-Q for the third quarter of 2015, confirming the financial restatements from the January 5 disclosure. Nobilis amended its 2014 Form 10-K to record net revenue of $16.19 million rather than the originally reported $20.25 million. (Id. ¶¶ 77-79).

The parties do dispute the explanation for Nobilis’s improper accounting and the resulting January 2016 restatements. No-bilis contends that it made “honest” mistakes in applying “obscure” accounting rules.1 Nobilis asserts that it discovered the mistakes when it switched to a more sophisticated national auditing firm in September 2015 and then promptly took steps to remedy the errors and disclose their effects. (Docket Entry No. 28 at 8-10). Schott alleges that Nobilis and its officers knowingly or recklessly misled investors by misrepresenting its revenues and assets. (Docket Entry No. 9 ¶ 67). Schott contends that the truth about these material misrepresentations was only gradually revealed to the market through a series of partial disclosures, contrary to Nobilis’s claims of prompt and vigorous disclosure.

B. The Allegedly Fraudulent Statements

Schott alleges that during the class period—between April 2, 2015 and January 6, 2016—Nobilis made false or misleading statements in its:' (1) 2014 Form 10-K; (2) 2015 first quarter Form 10-Q; (3) 2015 second quarter Form 10-Q; (4) 2015 Form S-l; (5) amendment to the 2015 second quarter Form 10-Q; and (6) amendment to the 2015 Form S-l. (Id. ¶¶ 51-67). The [945]*945following summarizes each alleged misrepresentation:

A. Nobilis’s 2014 Form 10-K, filed on April 2, 2015, reported net income of $20.25 million and recognized $6.43 million in accounts receivable from the Athas acquisition. (Id. ¶ 51-53). Nobilis later amended the Form 10-K to record only $16.19 million in net revenue and lowered the value of the Athas accounts receivable by $1.7 million. (Id. ¶¶ 67, 79).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Izadjoo v. Helix Energy Solutions Group, Inc.
237 F. Supp. 3d 492 (S.D. Texas, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
211 F. Supp. 3d 936, 2016 U.S. Dist. LEXIS 134829, 2016 WL 5539756, Counsel Stack Legal Research, https://law.counselstack.com/opinion/schott-v-nobilis-health-corp-txsd-2016.